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INTRODUCTION 
 Vitiligo is an ‘idiopathic’ acquired depigmenting disorder 
characterized by the loss of functional melanocytes from the epidermis. It is 
the most common pigmentary disorder and it involves complex interaction of 
environmental and genetic factors that ultimately contribute to melanocytes 
destruction, resulting in the characteristic depigmented lesions1. 
Vitiligo can be extremely disfiguring, leading to significant patient 
morbidity. Low self esteem, poor body image and poor quality of life has 
been found in patients with vitiligo, including significant psychiatric 
morbidity. This is of particular concern for children and adolescents, as they 
are in their formative years and developing their sense of self[2]. 
Vitiligo is perhaps the most frequent depigmenting disorder[³], 
occurring with a prevalence varying across populations, apparently being 
less frequent in Caucasians[4] (0.38%), African[5]  (0.34%), and Chinese[6] 
(0.0093%) than in Indians[7&8] (0.46–1.13%). Not so commonly, higher 
prevalence may appear among isolated populations. Its pathogenesis has 
been associated with genetic predisposition, autoimmune phenomenon and 
neural and growth factor dysregulation as well as inherent cellular metabolic 
defects leading to melanocyte apoptosis. 
The phenotypical expression of vitiligo is polymorphic, and several 
types of vitiligo are distinguished on clinical presentation. The natural course 
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of vitiligo is gradual, unpredictable and difficult to control. However, 
sometimes the disease persists in a stable status for a long time.[9] 
Vitiligo possess a treatment challenge and will remain so until we find 
treatments that give consistent, and long-term cure by repigmentation. 
Several treatment modalities have been advocated including topical therapy 
with potent topical corticosteroids, calcipotriol,  tacrolimus, pseudocatalase 
therapy and other modalities like melanocyte transplantation, skin grafting, 
cosmetic camouflage or self tanning preparations and psychological therapy. 
But these are often unsatisfactory for generalised Vitiligo, for which NB 
UVB and PUVA are the most important therapies.[10] 
In 1974, Parish successfully introduced a treatment combining 8-
methoxypsoralen and UVA called PUVA using newly developed Henselar 
high intensity artificial UVA light. The combination treatment of Psoralen 
with ultraviolet A (PUVA) therapy is a standardised therapy for vitiligo and 
is still the mainstay for non segmental vitiligo. Interestingly two-thirds of 
patients receiving psoralens and ultraviolet light found the treatment 
worthwhile, meaning that even if treatments are only partially effective, they 
may achieve psychosocial relief. 
The clinical studies with NBUVB in vitiligo are few. Earlier reported 
studies were mostly done in the western population and the studies in the 
darker race, including Indians, is limited. Narrow-band ultraviolet B 
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(NBUVB) is an emerging, effective and safe therapy for vitiligo. It is as 
effective as PUVA without many side effects. In 1997, Westerhof and 
Nieuweboer-Krobotova were the first to study the effect of NBUVB in 
vitiligo. NBUVB therapy has also been reported to be safe in childhood 
Vitiligo [11]. 
Recent reports have shown that NBUVB can induce significant 
repigmentation in either generalized or segmental  vitiligo.  It inhibits the 
induction and secretion of cytokines, and stimulates inactive melanocytes in 
the outer root sheath of hair follicles to proliferate and migrate into vitiligo 
lesions. In comparing the treatment of vitiligo with  NBUVB radiation 
versus topical PUVA, Westerhof concluded that UVB therapy was slightly 
more effective, produced faster repigmentation and had fewer side-effects. 
However, narrowband UVB therapy is not readily available and implies 
significant start-up expenses.[12]  
There are only few studies to compare the safety and efficacy of 
NBUVB therapy & PUVA therapy in the treatment of vitiligo. More number 
of studies to compare the same is required. Hence this prospective study is 
conducted. 
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AIMS OF THE STUDY 
 
To compare the efficacy and safety of PUVA therapy and NBUVB 
therapy in the treatment of Vitiligo vulgaris in terms of  
• Time taken for initial repigmentation  
• Mean grade of treatment response  
• Colour match  
• Psychological satisfaction  
• Side effects  
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REVIEW OF LITERATURE 
HISTORICAL ASPECTS 
        Vitiligo is a disease that was observed very early in history, and most 
ancient civilizations and religions had some type of reference about the lack 
of pigmentation. One of the earliest terms was "Kilas" in the Rig Veda, 
which means white spotted deer.  
        The Ebers Papyrus in 1550 BC mentioned two forms of depigmentation 
that could be interpreted as leprosy or depigmentation resembling vitiligo. 
By 1400 BC white leprosy spots were called Sweta khushtha in the Atharva 
Veda.In 1200 BC Japanese Shinto prayers have described depigmentation 
resembling vitiligo in the book called Amarakosa. Around 600 BC, the 
Ashtanaga hridaya explained prognostic factors for depigmentation. In 200 
BC, the Indian book Manu Smriti described "Sweta Kushtha" meaning 
"white disease" probably referring to vitiligo.In  Tamil Nadu  vernacular 
name “ven Kushtha “ was used from older days to describe Vitiligo. 
          Years later, the term vitiligo was perhaps derived from the latin word 
“vitelius” and used to describe the white flesh of calves, and finally the word 
vitiligo was  used by Celsus in his classic Latin book De Medicina in the 
first Century, Which has become established since then.[13] 
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EPIDEMIOLOGY 
       Vitiligo is perhaps the most frequent depigmenting disorder, occurring 
with a prevalence varying across populations, apparently being less frequent 
in Caucasians (0.38%)4, African Caribbean5 (0.34%), and Chinese6 
(0.0093%) than in Indians7&8 (0.46–1.13%). Based on some dermatology 
outpatient records, the incidence is roughly estimated as 3 -4% in India14. 
          Vitiligo may appear at any time from birth to senescence, although the 
onset is most commonly observed in persons aged 20-30 years. Onset of 
Segmental type of  Vitiligo is usually in childhood within 10 years. Vitiligo 
is rarely seen in infancy or very old age. The incidence between the sexes 
follows general population pattern without any particular predilection. A 
female preponderance has been reported for vitiligo, but it is not statistically 
significant and the discrepancy has been attributed to an increase in reporting 
due to cosmetic concerns by female patients. 
         Vitiligo mostly affects people with skin types III and IV. A higher 
incidence has been reported among patients with atopic dermatitis.[14] 
AETIOPATHOGENESIS 
 Vitiligo is a multifactorial polygenic disorder with a complex 
pathogenesis.  Although several theories have been proposed for the loss of 
melanocytes in Vitiligo, the precise cause remains unknown. Besides a 
genetic predilection, diverse epigenic factors also play role in 
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etiopathogenesis.[14] The Various Theories including  autoimmune, 
cytotoxic, biochemical, anti oxidant and neural have been proposed for 
destruction of melanocytes. [15] 
Autoimmune Theory: 
There is great anecdotal evidence that an autoimmune disorder causes 
the destruction of melanocytes, and this theory is now generally accepted as 
the common cause of vitiligo. It is known that  vitiligo appears in 
conjunction with several other autoimmune disorders, such as juvenile 
diabetes mellitus, Thyroid Disease,[16] Addison's disease, and pernicious 
anemia. Organ-specific antibodies can often be seen in patients with vitiligo.  
The immune system raises antibodies or cytotoxic T cells to damage 
melanocytes. Proving this theory, there is histological evidence in vitiligo 
patients that apoptosis is occurring in the depigmented skin lesions. Some 
research suggests that  the immunoglobulins may bind to tyrosinase related 
proteins[17] 1 and 2, which are important for melanogenesis.  
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Neural Theory:  
 Peripheral nerve endings may secrete a substance that is cytotoxic to 
melanocytes and causes their destruction. This theory is supported by the 
segmental variety of vitiligo, which occurs in specific dermatomes, 
indicating the skin is possibly only being affected by the nerves of that 
specific dermatome. Additionally, vitiligo appears with certain neurological 
disorders such as encephalitis, and trauma that causes peripheral nerve 
damage.[18] Nerve endings in depigmented areas were seen to produce 
abnormal neuropeptides and nerve growth factors, and displayed axonal 
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degeneration-these abnormal chemicals may be toxic to melanocytes. 
Additionally, depigmented areas showed some abnormal autonomic 
function, such as increased adrenergic tone, increased norepinephrine, and an 
increased concentration of catecholamines.[19] These data then suggest that 
neurotransmitter release could directly or indirectly relate to melanocyte 
destruction and depigmentation.[20]  
Self Destructive Theory:  
It is known that some of the intracellular pre-melanogenesis 
metabolites are toxic to melanocytes, such as dopa and dopachrome. 
Normally melanocytes possess cellular measures to counteract these toxic 
substances, but it is believed that cells may lose the ability to counteract 
these toxic metabolites and are destroyed by leakage of metabolites into the 
cytoplasm.[15] There is evidence that certain hydroquinone derivatives which 
are similar to these intra-cellular metabolites cause leukoderma 
experimentally. [21] 
The impaired redox status theory :  
Oxidative stress has been suggested to be the initial event in the 
pathogenesis of melanocyte degeneration with H2O2[21][22] accumulation in 
the epidermis of patients with active disease (12). Defective recycling of 
tetrahydrobiopterin has been reported in vitiligo epidermis, associated to the 
intracellular production of H2O2[21][23] . In addition, an alteration in the 
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antioxidant pattern with a significant reduction of catalase activity has been 
demonstrated in both lesional and non lesional epidermis of patients[21], as 
well as in melanocytes[22] . However, the antioxidant imbalance has been 
confirmed also in peripheral blood mononuclear cells of active vitiligo 
patients; it was correlated to an increased intracellular production of reactive 
oxygen species and appeared to be due to a mitochondrial impairment[24]. 
These findings support the concept of a possible systemic oxidative stress in 
vitiligo.  
Growth Factor Defect Hypothesis:  
A study in the 1980's found that melanocytes in lesions from Vitiligo 
exhibited "defective growth and passage capacities." The researchers noted 
that the growth defects of the melanocytes were partially corrected by adding 
a growth factor to their culture, suggesting that growth defects may be part 
of the pathogenesis of Vitiligo. In depigmented areas, cellular analysis 
showed that there were melanocytes but they grew poorly. These data 
suggest that growth defects appear to play a role in vitiligo[15] 
Genetic Influences:   
A positive family history has been reported in about 20% of patients 
with vitiligo and it has been found in monozygotic twins. Studies have 
shown that vitiligo does not follow a simple Mendelian pattern, but it is more 
likely coded polygenically[25]. There has been some evidence both proving 
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and disproving the involvement of the HLA system in the occurrence of 
Vitiligo[26]. Several genes and chromosomal regions have been implicated in 
susceptibility to vitiligo, but none has been confirmed so far[27]. In addition, 
several HLA abnormalities have been associated with vitiligo, including 
association with DR4, B13, BW35, and A30[28]. So, it is believed that genetic 
factors probably play a key role in the pathogenesis of vitiligo, but the exact 
cause is unknown[15]. 
Melanocytorrhagy: a newer concept in Vitiligo  
It proposes that vitiligo is a primary melanocytorrhagy disorder with 
altered melanocyte responses to friction and possibly other types of stress,   
inducing their detachment and subsequent transepidermal loss.  Further 
studies are needed to prove this. Dendrites of melanocytes not only help in   
melanosomes transfer to the surrounding keratinocytes but also help 
melanocytes to adhere to basal membrane. Cultured Vitiligo melanocytes 
show stubby dendrites. Similarly, the addition of H2O2 in established 
cultures of normal melanocytes induces a loss of dendrites and in some cases 
melanocyte detachment. The increased release of catecholamines might be 
an aggravating factor of Non Segmental Vitiligo(NSV). It is suggested that 
in adhesion-deficient NSV melanocytes, dendrites are lost in response to 
reactive oxygen species or by increased release of catecholamines and 
exaggerates transepidermal loss. Besides defective adhesion and dendritic 
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loss, other abnormalities may lead to a decrease in frictional resistance of 
melanocytes in NSV and eventually to their detachment by mechanical or 
chemical injury[29]. 
Convergence Theory:  
Following genetic studies, researchers have begun to lean towards a 
multi-faceted etiology for vitiligo, that combines components of the above 
mentioned theories and genetics. This theory states that genetic influences 
have a role in causing vitiligo in addition to other elements, such as stress, 
accumulation of toxic compounds, infection, autoimmunity, mutations, and 
impaired melanocyte proliferation[30].  
CLINICAL FEATURES 
         Vitiligo manifests as acquired white or depigmented macules or 
patches. The lesions are usually well demarcated, sometimes may be ill-
defined at the edges and they are round, oval, or linear in shape, rarely 
irregular. Lesions enlarge centrifugally over time at an unpredictable rate. 
Lesions range from millimeters to centimeters in size. The most common 
sites of vitiligo involvement are the face, neck, scalp and areas subjected to 
repeated trauma including the Bony prominences, extensor aspect of 
forearm, ventral side of wrists, dorsal aspect of hands and feet[14]. 
          Involvement of the mucous membranes is frequently observed in the 
setting of generalized vitiligo. Vitiligo often starts around body orifices such 
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as the lips, genitals, gingiva, areolas, and nipples. Body hair in vitiliginous 
macules may be depigmented (leukotrichia). Vitiligo of the scalp usually 
appears as a localized patch of white or grey hair, but total depigmentation of 
all scalp hairs may rarely occur. Leukotrichia may indicate a poor prognosis 
with regard to repigmentation. Spontaneous repigmentation of depigmented 
hair in vitiligo does not occur.   
      Trichrome vitiligo has an intermediate zone of hypochromia located 
between the achromic center and the peripheral unaffected skin.  This results 
in three shades of colour - brown, tan, and white. Quadrichrome Vitiligo is 
another variant of vitiligo which refers to the fourth zone of marginal 
hyperpigmentation in addition to trichrome vitiligo. Pentachrome vitiligo 
with five shades of colour has also been described.  Marginal inflammatory 
Vitiligo is Vitiligo patch with a red, raised border which may appear several 
months or years after the initial onset. A mild pruritus may be present in 
marginal inflammatory Vitiligo.  Blue vitiligo is vitiligo macules occurring 
in the sites of postinflammatory hypermelanosis[31]. 
CLASSIFICATION. 
Several types of vitiligo are distinguished according to the distribution 
of the achromic lesions. According to the distribution, extension, and 
number of white patches, vitiligo is divided into generalized (vulgaris, 
acrofacial, mixed, and universalis) and localized (focal,segmental, and 
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mucosal) types[32]. Depending upon the progression, Vitiligo can be 
classified into stable and unstable Vitiligo[14] 
Localized Vitiligo :  
1.Focal Vitiligo 
Focal vitiligo is characterized by depigmented patch (or a few patches) 
in a focal and non dermatomal distribution.  
2.Segmental Vitiligo 
Features of the segmental type include depigmented macules in a 
quasi dermatomal and unilateral distribution. This type of vitiligo has earlier 
age of onset and usually stabilizes within a year or two of its onset; it’s 
usually not associated with other autoimmune diseases or a familiar pattern 
of inheritance.  
Generalized Vitiligo: 
1. Vitiligo vulgaris - The most common form of Vitiligo has a 
generalized distribution. This variety of Vitiligo  is symmetrical and 
usually involves the extensor surfaces of the hands, wrists, legs , 
axillae and offen the face and usually in a symmetrical pattern.  
2. Acrofacial Vitiligo - lesion tend to be predominantly distributed on 
acral parts of limbs, [hands and feet generally the fingers toes palms 
and soles] and face.  
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3. Vitiligo Universalis - In this type, the depigmentation is so widespread 
that only a few areas of normal skinremains 
COURSE OF THE DISEASE   
 The course of the disease is unpredictable and uncertain, most often 
showing a tendency towards slow progression. Lesions in the 
pseudosegmental type remain static for an indefinite period after a certain 
degree of regional extension. In Vitiligo vulgaris, lesions develop on 
different areas in succession with varying rapidity. In some, extension of 
individual lesions and development of new lesions at different sites occur in 
episodic bouts with the intervening quiescent period varying from weeks to 
years. Many lesions may remain static for an indefinite period or show some 
degree of spontaneous regression with the development of pigment spots. 
Others may show repigmentation of some lesions, extension of others, and 
appearance of new lesions at other sites simultaneously. At times, the 
pigment spots that occur spontaneously or in response to therapy disappear 
but may reappear. Complete spontaneous cure is extremely rare. Sometimes 
residual depigmentation may be left behind after repigmentation.[14] 
HISTOPATHOLOGY: 
Histopathological examination of vitiligo lesions using melanocyte-
specific stains has shown few melanocytes in early lesions and a lack of 
melanocytes in well-established lesions[31]. In patches with hyperpigmented 
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borders, the margins were found to contain enlarged melanocytes with 
elongated dendritic processes containing melanin. A lymphohistiocytic 
infiltrate along with focal basal layer vacuolar changes has been observed in 
marginal tissue. Significantly more infiltrate and other inflammatory changes 
were appreciated in marginal areas and early lesions in one study[33]. 
VITILIGO THERAPY  
Depigmentation in vitiligo should be initially treated with medical 
therapy. When therapy fails in spite of appropriate interventions, vitiligo 
may become refractory and stable. Surgical therapy indicated in selected 
patients with refractory Vitiligo[34].   
MEDICAL THERAPY 
As a general rule, although not defined by evidence based findings or 
validated for every medication, topical therapy for vitiligo is usually 
recommended when depigmentation is less than 10–20% of the skin surface 
and systemic therapy when exceeding these limits. But when topical therapy 
of small areas fails, systemic treatment may be indicated. Repigmentation is 
slow and patients should be advised about compliance and patience  
Medical therapy will be divided in the following categories:                    
1) corticosteroids 2) immunomodulators 3) ultraviolet radiation 4) lasers             
5) alternate therapy 6) depigmentation and 7) psychological support and 
camouflage. Selection of a specific therapy depends on effectiveness 
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supported by evidence based information and according to the 
dermatologist’s experience since diverse treatments may offer comparable 
results. Alternate therapy should be tried when therapeutic failures to first 
line treatments occur[34]. 
Topical corticosteroids:  
This is a first line therapy for localized vitiligo,. Corticosteroids class 
3 and 4 were the most effective for localized Vitiligo[35].  Topical potent and 
ultrapotent corticosteroids should be limited to 2–4 months to avoid local 
side effects (atrophy, telangiectasia, striae) and percutaneous absorbtion 
resulting chronic adrenal insufficiency[34]. 
Systemic corticosteroids:  
Systemic corticosteroids may arrest the progression of vitiligo and 
lead to repigmentation by immunosuppression[36]. As clinical improvement is 
experienced by patients who are receiving oral corticosteroid treatment for 
actively spreading Vitiligo, a reduction in complement – mediated 
cytotoxicity by autoantibodies to melanocytes, and a reduction of antibody 
titre to surface antigens of melanocytes are noted in their serum samples.  
Immunomodulators 
Initial observations suggested that tacrolimus inhibits T-cell activation 
by down-regulating the transcription of genes encoding proinflammatory 
18 
 
cytokines. It offers the advantage of prolonged treatment without the adverse 
effects seen in the long-term use of corticosteroids.[34][36]  
Lasers:  
The 308-nm excimer laser produces faster repigmentation rates than 
any other medical method so far reported[37]. The 308-nm excimer laser 
demonstrated its efficacy and good tolerance for localized vitiligo. 
Repigmentation seems to be faster than with NB UVB, except in extremities 
and bony prominences. Since no data for skin cancer risk are available, 
caution is adviced. 
Alternate and adjuvant therapies: 
Vitamin D-3  
Vitamin D-3 analogues calcipotriol and taclacitol have been used 
topically in vitiligo, where modulation of the local immune response on 
specific T cell activation occurs; they also influence melanocyte maturation 
and differentiation and up-regulate melanogenesis through pathways 
activated by specific ligand receptors, such as ET receptor and c-kit[38]. 
Depigmentation 
Some selected patients with vitiligo universalis may benefit from 
depigmentation of unsightly residual pigmented patches on facial and 
exposed areas. Depigmentation may be achieved with 20% monobenzone 
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which is first applied with a patch test for 48 h to detect hypersensitivity; 
then, twice daily applications are followed by depigmentation within the 
next 6–12 months[39]. 
Psychological support and camouflage 
If all treatments have failed; the patient does not wish to undergo 
treatment; or while treatment is ongoing, cosmetic cover-ups can be very 
useful. A recent study investigated quality of life in vitiligo patients and the 
effect of using camouflage. Using camouflage, particularly for the face, head 
and neck improved the patients’ quality of life. 
Surgical therapy 
Until 1983, most articles referred to vitiligo as a condition treated 
exclusively with medical therapy. Early work with thin dermoepidermal 
grafts suggested that surgery had a place for vitiligo depigmentation[40]. Later 
on, the value of grafts for vitiligo therapy was confirmed.       
Essentially five basic methods for melanocyte transplantation have been 
described:  
1) non-cultured epidermal suspensions  
2) thin dermo-epidermal grafts 
3) suction epidermal grafting  
4) minigrafting and punch grafting 
20 
 
5) in-vitro cultured epidermis with melanocytes or pure melanocyte 
suspensions.  
All methods provide good to excellent results and the most important 
factors for success are patient selection and surgeon’s expertise[34].  
PHOTOTHERAPY AND PHOTOCHEMOTHERAPY 
Historical background 
The ancient Egyptians were the first to recognize the beneficial effect 
of sunlight on humans.  Herodot in 525 BC correlated the strength of the 
human skull to the degree of sun exposure. The ancient Greeks (Hippocrates 
460- 375 B.C., Obrasius of Pergamon 325-403 A.D.) used sunlight for a 
variety of illnesses including edema and diseases of the abdomen and 
kidneys. 
Thereafter followed the dark period of phototherapy. In the Middle 
Ages, where pale skin was taken as a sign of beauty and wealth, 
phototherapy floundered. Newton in 1672 discovered the spectrum of visible 
light. Ultraviolet light was discovered in the early 1700s. 
In 1895, modern phototherapy began when Niels Finsen, the father of 
modern ultraviolet therapy, used a carbon arc source to treat lupus vulgaris. 
He was awarded the Nobel prize in 1903. 
In 1923, Goeckerman introduced his regime (artificial broadband 
UVB + coal tar) for psoriasis. In 1953 Ingram introduced his regime 
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combining artificial broadband UVB and dithranol. Subsequently, it was 
found that UVB on its own was also efficacious in dermatological therapy. 
Van Weelden in 1984 demonstrated the clinical efficacy of narrowband 
UVB. Since then, it has been proved to be more effective than broadband 
UVB in various skin disorders and is increasingly used in various parts of 
the world[41].  
The history of photochemotherapy dates back to ancient times. As far 
back as 2000 B.C., the Indians and Egyptians used the pigment-stimulating 
properties of the psoralen-containing Bavachee plant (Psoralea corylifolia) 
and Ammi majus respectively for the treatment of Vitiligo.   Only 3 
millennium later in 1947 Fahmy, an Egyptian pharmacologist, isolated 
psoralen compounds from Ammi majus. The 1960s and 70s were an era 
where the basic pharmacology of the psoralens was studied. In 1974, Parish 
successfully introduced a treatment combining 8-methoxypsoralen and UVA 
called PUVA using newly developed Henselar high intensity artificial UVA 
light[42][43]. 
PHOTOBIOLOGY 
Interaction between UV radiation and the skin. 
 UV radiation that reaches the skin is either reflected or absorbed by 
structures of the skin. While UVC (<280 nm) is mostly absorbed in the 
stratum corneum, UVA (320–400 nm) shows deeper penetration than UVB 
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(280-320nm). Thus UVB is mainly absorbed by epidermal components, 
including keratinocytes, melanin and Langerhans cells. Biological effects of 
UV radiation are generated through interaction with absorbing molecules 
called chromophores..Ultimately, the interaction of UV with chromophores 
can lead to a multitude of effects such as induction of oxidative stress and 
activation of transcription factors, as well as induction of damage to the cell 
membrane and DNA mutations[44]. 
PUVA 
Ultraviolet-A (UVA) is the name given to the waveband of 
electromagnetic radiation ranging from 320-400nm. UVA combined with a 
psoralen photosensitizing agent (8-methoxypsoralen or 5-methoxypsoralen) 
is known as PUVA or photochemotherapy.  
PUVA units are full body cabinets containing 6 feet 100W 
fluorescent low-pressure mercury bulbs., UVA lamps (TL100/209R) have 
black markings (e.g. FS72T12BLHO). Most units have 24 or 36 or 48 bulbs, 
and may be the same cabinet as BB-UVB and rarely NB-UVB bulbs. Hand 
& foot units contain 2 feet bulbs. 
Modern units have integrated dosimetry and the time to deliver the 
correct dose is automatically calculated. For older units, irradiance is 
checked manually prior to treatment using a specific UVA dosimeter and the 
treatment time for a specific dose determined according to a spreadsheet [45]. 
23 
 
Psoralens 
Psoralens are chemical compounds derived from certain plants such 
as ‘Ammimajus’ found in Egypt and Indian plant Bavachee which is also 
called as Psoralea corylifolia. Psoralen has been found in more than 30 
plants such as lime, lemon, bergamot, parsley, celery, fig and cloves[46]. The 
medical use of these plants in the treatment of vitiligo by the ancient 
Egyptians dates back to as early as 1500 B.C. and by the Indians to 1400 
B.C. 
Psoralen and many of its derivatives are naturally occurring tricyclic 
furocoumarins. The derivative most widely used in photochemotherapy is 
8methoxypsoralen (8MOP, methoxsalen, xanthotoxin) which is principally 
of plant origin but it is available as a synthetic drug. The drug 4, 5, 8-
trimethyl psoralen (TMP, trioxsalen) is a synthetic compound which is less 
phototoxic after oral administration and is primarily used for the treatment of 
vitiligo. Newer psoralens under research are 5-methoxypsoralen (Bergapten, 
3-carbethoxypsoralen and angelicin). The photobiological activity of 
angelicin is low. The introduction of one or more methyl groups results in 
the increased photo binding capacity of angelicin towards DNA. These 
various methyl derivatives of angelicin are called the new angelicins. 4,, 6-
methyl angelicin is the most promising of the new angelicins[47]. 
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Pharmacology 
When taken by mouth, methoxsalen (8-MOP) is absorbed from the 
gastrointestinal tract. Increased photosensitivity is present 1 hour after the 
dose, reaches a peak at about 2 hours and disappears after about 8 hours. The 
absorption of methoxsalen and hence clinical response may be altered by 
concomitant food ingestion as well as by differences in drug formulations. A 
liquid preparation in soft gelatin capsules or a microenema gave higher 
serum concentration more rapidly than did crystalline methoxsalen in tablets 
or capsules. Methoxsalen has high but variable intrinsic metabolic clearance 
and is almost completely metabolised. Individuals with a high clearance and 
low maximum serum concentration usually show reduced sensitivity to 
PUVA. These patients i.e. those not responding to usual dose may respond to 
higher doses of psoralens or to the administration of the drug by other routes 
such as bath water delivery. After oral administration the drugs are 
metabolised in the liver by hydroxylation and glucuronide formation and 
over 90% is excreted in the urine within 12 hours. Psoralen appears to be 
distributed to all tissues after oral administration and there is no risk of 
accumulation in any organ in patients with normal liver and kidney function. 
When applied locally 8-MOP rapidly penetrates the skin and can be 
detected in the urine after 4 hours. The plasma levels of 8-MOP in patients 
receiving total body topical 8-MOP are comparable to those found during 
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oral 8-MOP ingestion. The plasma concentration of TMP after bath 
treatment is only approximately 1% of the plasma after oral ingestion. 
Mechanism of action 
The exact mechanism by which psoralens produce cutaneous 
photosensitivity reactions is not precisely known. Mode of action of 
psoralens does not occur at one level, but at several levels simultaneously 
including cellular DNA, RNA, proteins, mitochondria, cell membrane lipids 
etc. In the normal skin or in the skin of psoriatic patients, psoralen induced 
skin photosensitization involves two distinct types of reactions occurring 
independently of each other and concurrently when psoralen treated skin is 
exposed to 320 - 400nm radiation. 
1. Type I is an anoxic reaction not requiring oxygen and the site of 
cellular damage is primarily in DNA of cell nuclei. 
2. Type II is a sensitized reaction dependent on oxygen and involves 
the formation of oxygen reactive species and free radicals. 
In these 2 modes of reactions, the reactive form of psoralen is in its 
triplet state. The major photochemical reaction of psoralen contributing to 
the cellular damage is undoubtedly the formation of monofunctional and 
bifunctional adducts of psoralen with pyrimidine bases in DNA . The 
formation of monofunctional and bifunctional photo adducts in DNA results 
in immediate inhibition of DNA synthesis. It is also possible that PUVA may 
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affect specific cells such as lymphocytes or polymorphonuclear leucocytes. 
A decrease in the percentage of circulating T-lymphocytes following PUVA 
treatment has been reported.  
The mechanism by which PUVA induces repigmentation in vitiligo 
remains unclear although the following ways have been speculated.  
1. By increasing the number of functional melanocytes as a result of 
mitosis or by activation of dormant melanocytes in the epidermis and 
appendages. 
2. By inducing hypertrophy of melanocytes and an increased 
arborization of their dendrites. 
3. By augmenting the development and melanization of melanosomes 
and increasing the transfer of melanosomes to keratinocytes. 
4. By stimulation of tyrosinase activity 
5. By enhancing the migration of activated melanocytes from skin 
appendages 
6. By generating a suppressor cell population which suppresses the 
stimulus for melanocyte destruction during therapy[48] 
Indications of PUVA   
 
The indications are: (1) Psoriasis (2) vitiligo (3) cutaneous T-cell 
lymphoma (4) atopic dermatitis (5) lichen planus (6) urticaria pigmentosa (7) 
preventive treatment for photodermatoses like (a) polymorphic light eruption 
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(b) solar urticaria (c) chronic actinic dermatosis (d) persistent light reaction 
(e) hydroa vacciniforme and (8) miscellaneous conditions such as acute and 
chronic pityriasis lichenoides, lymphomatoid papulosis, pityriasis rubra 
pilaris and alopecia areata.[48] 
Methods of treatment 
For oral 8-MOP, 0.4 to 0.6 mg/kg body weight is usually effective, 
although some may need more, and others less. For 5-MOP, double this dose 
is necessary (1-1.2 mg/kg body weight). Poor response to PUVA can be due 
to inadequate absorption of the drug or a delayed peak levels of psoralen in 
the skin. 
The minimal phototoxic dose (MPD) is typically measured as follows.  
1. 0.5 mg/kg of methoxsalen is ingested 2 hours prior to exposure.  
2.  A template with four or five 1 to 2-cm squares is applied to a non-sun 
exposed area (often volar surface of forearm or buttocks). The Diffey 
device is convenient for this purpose. The templates block the radiation by 
nil, a half, three-quarters and seven-eighths. Surrounding skin is protected 
from exposure. The squares are exposed to a geometric series of 
increasing doses of UVA according to estimated skin type. (e.g. 1, 2, 4, 8 
J/cm2).  
3. Test sites are outlined with a skin marker so that they can be identified.  
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4. The response is measured 72-96 hours later. The MPD is the lowest dose 
of UVA radiation that produces pink erythema with distinct borders.  
5. The test may be repeated using a different range of test doses if either all 
or none of the test sites have erythema.  
Dose regimen for PUVA 
To establish the appropriate starting dose of UVA,MPD is 
determined and the initial dose is fixed at 70% MPD. Or the dose is selected 
according to estimated skin type as shown in the table  If case of obese 
patients, skin is assumed one type less as irradiance will be greater as the 
patient's body is closer to the bulbs. Dose has to be slowly increased with 
weekly increments. Patients with Skin type 1 & 2 were treated twice weekly 
to reduce chance of erythema. 
Skin type Initial dose (J/cm2) Increments 
Maximum 
dose (J/cm2) 
Skin type 1 1 30 % each     week 5 
Skin type 2 2 30% each      week 8 
Skin type 3 3 30% each treatment 20 
Skin type 4 4 30% each treatment 20 
Skin type 5 5 30% each treatment 20 
Skin type 6 6 30% each treatment 20 
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The development of any phototoxic erythema precludes further dose 
increments. It may be very difficult or impossible to treat skin phototype 1 
patients with PUVA. The patient should be examined prior to each 
treatment. Erythema may be localised or generalised. Localised erythema 
can be protected allowing incremental exposures to the rest of the body, as 
scheduled, but generalised erythema should result in  changes to the 
schedule. No erythema - dose is according to schedule. Faint erythema 
(pink) or mild itch - dose is held at previous level. Definite or tender 
erythema(pink) or significant  itch - treatment is withhold until erythema 
resolved [45]. 
US protocol 
The first treatment exposure dose is based on the skin typing and the 
patients are treated either twice or thrice a week. Dose increments range 
from 0.5 - 1.5 J/cm2 depending on erythema production and therapeutic 
response[47]. 
European protocol 
The first treatment is administered after determination of the 
individual's minimum phototoxic dose (MPD) and the initial UVA dose is 
70% of the patients MPD. Four treatments are given per week. Two 
treatments are given on consecutive days followed by a rest on day 3 after 
which treatment is resumed for 2 days. Increments of dose are performed 
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only after the first four treatments if no more than a pink erythema has 
developed and range from 0.5 to 2 J/cm2 depending on the patient's MPD 
ability to develop pigmentation[47]. 
Manipal protocol: 
The usual starting dose is 4 - 6J/cm2. Dosage increments of 0.5 J/cm2 
are done each time till a maximum of 18 J/cm2 is reached. Treatment is given 
thrice or four times a week[47]. 
Precautions to be taken during PUVA therapy 
Because of the greater likelihood of photoageing and carcinogenesis, 
PUVA should not be used in children. It should only be used in patients who 
are able to comprehend and comply with instructions. Psoralen requires 
hepatic metabolism and renal excretion therefore should be used with great 
care in those with hepatic or renal disease. It is not teratogenic, but like other 
medications should be avoided in pregnancy if possible. It is excreted in 
breast milk, so breast-feeding mothers should not receive PUVA. 
Carbamazepine, phenytoin and phenobarbitone reduce the level of 
methoxsalen. Systemic methoxsalen inhibits liver enzymes so that it may 
significantly increase serum levels of concomitant caffeine or 
theophylline[45].  
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Adverse side effect of PUVA therapy 
Acute side effect 
• Anorexia 
• nausea 
• headache 
• dizziness 
• Acute phototoxicity: tender erythema &/or deep pruritus for several 
weeks or longer  
• Ocular toxicity: photokeratitis causing grittiness, pain, photophobia, 
tearing & blepharospasm  
• Polymorphic  light eruption 
• Irritable erythematous papules on skin that is not usually sun-exposed  
• Herpes simplex reactivation........  
• Koebnerisation from phototoxicity   
• Rarely: asthma, hepatitis, drug fever, rash, photo-onycholysis, ankle 
oedema, hypertrichosis  
Long-term side effect 
• Photo-ageing: Wrinkling, PUVA freckling, xerosis, telangiectasia, 
elastosis, white macules, skin atrophy, cataracts  
• Solar keratoses, squamous cell carcinoma (SCC), basal cell carcinoma 
(BCC) & melanoma. Risk of SCC is greater if >200 treatments, 
especially for skin type 1 & 2 and if there are other predisposing 
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factors such as excessive sun exposure. The risk of genital skin cancer 
is high so genitalia should always be covered during PUVA 
therapy[45]. 
UVB PHOTOTHERAPY 
Phototherapy with ultraviolet (UV) radiation of wavelengths between 
280 and 320 nm (UVB) is a safe and effective treatment for a variety of 
diseases. In addition to standard broadband UVB (BBUVB), narrowband 
phototherapy with fluorescent bulbs emitting  monochromatic UV around 
311 nm (NBUVB) has become an important treatment for diseases such as 
psoriasis, atopic dermatitis and vitiligo.[49]  
Mechanism of action  
UV radiation alters immunological function  and UVB can increase 
the production of pro-inflammatory substances like prostaglandins (PG) or 
tumour necrosis factor (TNF), as well as the production of anti-inflammatory 
factors like interleukin (IL)-10, alpha-melanocyte stimulating hormone 
(MSH) and PGE2[50] 
UVB down-regulates the expression of intercellular adhesion 
molecule (ICAM)-1, reduction of the density and function of Langerhans 
cells in the skin and their migration to the draining lymph nodes is more 
pronounced with BBUVB than with NBUVB. Infiltrating epidermal T cells 
as well as mast cells are susceptible to UVB-induced apoptosis. NBUVB 
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appears to have a more immunosuppressive effect than BBUVB on natural 
killer cell activity, cytokine responses and lymphoproliferative responses of 
peripheral blood mononuclear cells and photo-isomerization of trans- to cis-
urocanic acid is more effective with NBUVB than with BBUVB  with 
urocanic acid photoconversion being mainly induced by wavelengths 
between 310 and 340 nm.[51] 
 NBUVB suppresses the production of interferon (INF) -  α, IL-2 and 
IL-12 and increases that of IL-4 and IL-10, which together could account for 
a shift of the immune response in the direction of T-helper (Th)2-like 
responses . The shift from an IFN-α-dominatedTh1 to an IL-4 dominated 
Th2 response appears t o be one of the major factors determining the 
therapeutic efficacy of NBUVB phototherapy.[52]  
NB UVB may exect its effects in vitiligo in a two – step process. 
Both steps may occur simultaneously, that first being the stabilization of the 
depigmenting process and the second, the stimulation of residual follicular 
melanocytes. The well documented inmmunomodulating effects of UV 
radiation can explain stabilization of local and systemic abnormal immune 
responses. Its also likely that NB UVB similar to PUVA therapy. Stimulates 
the dopa – negative, amelanotic melanocytes in the outer hair root sheaths, 
which are activated to proliferate, produce melanin and migrate out ward to 
adjacent depigmented skin resulting in perifollicular repigmentation. 
34 
 
INDICATIONS FOR NARROWBAND UVB 
Phototherapy with NBUVB has been reported to be effective and 
safe for the treatment of  psoriasis, atopic dermatitis and vitiligo. Various 
other skin diseases can be treated successfully with NBUVB phototherapy, 
like parapsoriasis, initial mycosis fungoides, graft-versushost disease and 
pruritus, as well as acquired perforating dermatosis, lichen planus, lichen 
simplex chronicus, lymphomatoid papulosis, generalized granuloma anulare 
nummular dermatitis, pityriasis lichenoides chronica, pityriasis rosea, 
pityriasis rubra pilaris, pruritic folliculitis of pregnancy, seborrhoeic 
dermatitis, Schnitzler’s syndrome and Sneddon-Wilkinson disease.[49] 
ADVERSE EFFECTS OF NB-UVB 
Early side effects 
Early side effects of NBUVB include erythema and dryness of the 
skin. The maximum erythema occurs 8–24 h after irradiation. As patients 
over 70 years show a prolonged NBUVB-induced erythema, a more cautious 
approach to dose increment is recommended in the elderly.[54] 
Late side effects 
Chronic exposure to UV radiation induces premature ageing (photo 
ageing) of the skin, showing typical clinical signs of leathery appearance, 
wrinkling, reduced recoil capacity and increased fragility of the skin. [55] 
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VITILIGO TREATMENT RESPONSE ASSESSMENT 
Many vitiligo treatments have typically been analyzed using nominal 
binary scales in which the proportion of treated patients who either do or do 
not achieve a specified degree of repigmentation is reported and compared 
by nonparametric statistical approaches. The degree of repigmentation that 
defines success has often been set somewhat arbitrarily at 50% to 75% 
repigmentation based largely on the global impression of the overall 
response. There is currently no validated quantitative scale that allows 
vitiligo to be characterized parametrically.  
The primary advantage of using quantitative scales for evaluating 
vitiligo is that they provide direct estimates of the expected quantitative 
responses that patients might expect to achieve. In contrast, nominal and 
nonparametric methods can only estimate the proportion of patients who 
achieve a certain arbitrarily set level of response. Quantitative methods 
provide data that are generally more intuitive and meaningful to patients and 
physicians, while at the same time being more sensitive for detecting 
significant subtle treatment effects.[56] VASI scoring is one such quantitative 
method however which is not routinely perform. 
Vitiligo treatment response assessment scales followed by different 
authors are summarised in the table below.  
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Previous studies comparing PUVA and NBUVB therapy in Vitiligo 
In their meta analysis Njoo et al concluded that the difference 
between mean success  rate of NB – UVB  and  PUVA are not statistically 
significant although the former was comparatively more effective. [57] 
In their randomized double blind trial , Sami Sasi Yones et  al  found 
that 64% of patient in the NB UVB group showed greater  than 50 % 
improvement compared to 36% patient only in PUVA group.[58]  
In the open and  non -observer  blinded study comparing  the systemic 
PUVA and NB UVB in the treatment of vitiligo (A Bhatnager et  al ) The 
mean  repigmentation achieved in NB UVB group 52 .24% and PUVA 
group 44.7% which was  statistically not significant.[59]   How ever after 
excluding the resistant sites that is hands and feet The mean  repigmentation 
achieved in NB UVB group 67.57% and PUVA group 54.2% which was  
statistically significant. 
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The retrospective study by Parsad et al, PGI Chandigarh 23.6%  
showed marked to complete improvement and 36.8% moderate improvement 
in the PUVA treated group whereas in the  NB – UVB   group 41.9% 
showed marked to complete repigmention 32.2% showed  moderate 
improvement.[60] 
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MATERIALS AND METHODS 
 This randomised open prospective clinical study was conducted on 
forty Vitiligo vulgaris patients who attended outpatient clinic of 
Dermatology department at Tirunelveli medical college hospital, Tirunelveli 
over the period of 15 months from April 2009 to June 2010. Approval was 
obtained from the institutional ethical committee prior to the conduct of this 
study.  
PATIENT SELECTION 
Inclusion criteria:  
a. Age 18 to 65 years 
b. Body surface area involvement greater than 10% 
c. Stable Vitiligo  (Stable for more than one year)  
Exclusion criteria:  
a. Age less than18 years and more than 65 years  
b. Body surface area involvement lesser than 10% 
c. H/o Photosensitivity and Photo mediated disorders  
d. H/o administration of drugs causing photosensitization 
e. H/o skin malignancy, renal and hepatic diseases 
f. Pregnancy and Lactation   
g. Active Vitiligo  
h. Patient on any treatment for Vitiligo within previous 6 months  
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The name, age, sex, address, outpatient number were noted. Following 
detailed clinical history was taken. 
1. Time of onset of Vitiligo 
2. Course of the disease-stability and rate of progression 
3. Potential precipitating events including emotional stress and cutaneous 
trauma 
4. History of photosensitivity and drug causing photosensitivity  
5. History of any treatment(Systemic, topical)  
6. Any history of suggestive of  Diabetes Mellitus , Hypertension, 
Thyroid disease,  Anaemia and  other autoimmune diseases 
7. Family history of Vitiligo  
8. History of any psychological impact by the Vitiligo  
 All patients were examined under good light. Detailed dermatological 
examination including size, shape, number, color and distribution of lesions 
was done. Pattern of Vitiligo and mucosal involvements were taken into 
account. Presence of leucotrichia in the patch was also noted.  
Estimation of percentage of body surface area with Vitiligo was 
carried out by using rule of 9 (Wallace), 9% for head and neck (head 7%, 
neck 2%),  9% for each upper limb (arm 4%, forearm 3% hand 2%) 9% for 
the front of each lower limb (Thigh 5%, leg 2.5%, foot1.5 %) and 9% for the 
back of each lower limb (Thigh 5%, leg 2.5%, foot1.5 %). 9% for the front 
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of chest, 9% for the front of the abdomen,   9% for the upper back, 9% for 
the  lower back and 1% for the external genitalia. 
Palm size is taken as about 1% of body surface area for measuring 
small area of involvement. Any skin lesions suggestive of autoimmune 
disorders like Autoimmune thyroiditis, Diabetes mellitus, pernicious 
anaemia, Addison’s disease if present were noted. 
Laboratory investigations like routine blood examination (Hb, TC, DC 
& ESR), urine analysis, blood sugar, blood urea and serum creatinine, liver 
function tests, thyroid function test were done. ophthalmic examination was 
done to rule out cataract and retinal pathology   
Initial photographs were taken using canon digital camera before 
commencement of treatment, completion of every sixteen treatment sessions  
and at the end of the treatment.  
Patients were randomly allocated to receive either PUVA or narrow 
band UVB by means of a sequentially numbered list 
Treatment schedule, precaution to be taken during and after treatment, 
expected response, total duration of treatment and common side effects were 
explained to the patient. Informed consent was obtained from the patients 
before starting treatment. 
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Phototherapy unit: 
Full body phototherapy chamber containing 6 feet, 100W fluorescent 
UVA and NBUVB lamps total of 36 bulbs. This chamber has integrated 
dosimetry and the time to deliver the correct dose is automatically 
calculated. 
The following treatment methodology and assessment of response 
were adapted during the study between the two groups.  
TREATMENT SCHEDULE 
A. PUVA groups 
Patients were instructed to ingest trimethyl Psoralen 25  mg  tablet 
empty stomach two hours before UV exposure. Standard initial dose of 5 
Joules/cm 2 was given to all patients. Therapy was administered twice per 
week on Tuesdays and Fridays. Irradiation dose was increased by 0.5 Joules 
/cm 2 per week. During each treatment session, patients were instructed to 
shield their genitals and use photo protective goggles. Barring these 
protected areas whole body irradiation was performed. If lesion was present 
on the eyelids, patients were asked to close the eyes during treatment without 
wearing goggles. Patients were advised to apply sunscreen on exposed areas 
after treatment and to avoid excessive sun exposure. 
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B. Narrow band UVB 
Standard initial dose of 250mJ/cm 2 was given to all patients. Therapy 
was administered twice per week on Tuesdays and Fridays. Irradiation dose 
was increased by 50 mJ /cm 2 per week. During each treatment session 
patients were instructed to shield their genitals and use photo protective 
goggles. Barring these protected areas whole body irradiation was 
performed.  
Optimal constant dose  
The development of any phototoxic erythema precludes further dose 
increments. Erythema may be localized or generalized. If localized erythema 
present that parts were covered and allowing incremental exposures to the 
rest of the body, as scheduled. But when generalized erythema occurred, 
then the schedule was stopped until the resolution of erythema. Once 
erythema resolved, the optimal constant dose was held at the previous dose.  
Assessment of therapy  
Fortnightly repigmentation assessment including follicular 
pigmentation, shrinkage of the lesion and color of the lesion (diffuse 
pigmentation) was noted and recorded.   
The affected areas Photographs were taken on completion of every 16 
sessions. Comparison was made with the base line photograph to determine 
the percentage of improvement in body surface area of Vitiligo. 
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Repigmentation was graded in each topographical area as follows 
• Grade 0 = 0% ( No response) 
• Grade 1 =      1-25 % (Mild) 
• Grade 2 =  26-50% (Moderate) 
• Grade 3 = 51-75% (Good) 
• Grade 4= 76-99% (Very good) 
• Grade 5 =  100% (Excellent) 
Mean repigmentation in individual patients were calculated by adding 
the extent of repigmentation achieved in each topographical area after 
therapy and then dividing the  figure with the total number of tophographical 
areas bearing Vitiligo lesions. Mean repigmentation in the individual group 
was determined by adding the mean repigmentation of the individual patients 
divided by number of patients in each group.  
Colour of repigmentation was graded subjectively as somewhat 
darker, somewhat lighter or the same as compared with a normally 
pigmented surrounding skin. Time taken for onset of repigmentation was 
noted. Any adverse effects during treatment were noted. 
Psychological Assessment  
The subjective satisfaction of the patient is assessed by asking the 
question “How do they feel about the treatment?” The patient were 
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instructed to give any one of the following response 1.Unsatisfied                    
2.Satisfactory  3.Good 4.Very good 5.Excellent  
 This question is asked at the end of every 16 treatment sessions, and 
the response is noted and recorded. 
Termination of therapy  
 Treatment was stopped once 100% repigmentation was achieved or 
the 12 months period was completed whichever was earlier. Patient showing 
no response after 50 exposure was considered as a non responder and 
excluded from the study. 
Results were analised by students propotion ‘t’ test and students 
unpaired ‘t’ test. The effectiveness of therapy between two groups were 
compared by students unpaired ‘t’ test. Colour match, psychological 
satisfaction, and side effects of therapy were compared by chi- square test. 
The above statistical procedure were performed by statistical package 
SPSS(13.0). 
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RESULTS 
Out of the 20 patient enrolled for study in each group, only 15 patients 
completed the study. 5 patients in each group stopped due to various reasons 
within 3 months and so excluded from the study. In both groups there were 
no non responders after 50 treatment sessions.  
PUVA GROUP:  
1) Demographic profile 
 In PUVA group age of the patients ranges from 18-60. Mean age with 
Standard deviation (S.D) is 41.06±13.63. There are 4 males and 11 females. 
(Table 1&2) 
 The duration of disease ranges from 2 yrs to 15 years(yrs). Mean 
duration of Vitiligo with S.D is 4.53±2.19 yrs (Table:3). The body surface 
area affected by vitiligo ranges from 13% to 47%. Mean body surface area 
affected by vitiligo with S.D is 24.9±9.95 (Table:4). The duration of therapy 
ranges from 6 months to 8 months. The mean duration of therapy with S.D is 
6.85±0.99 months. 
2) Initial Repigmentation:  
 Time taken for initial repigmentation ranges from 4 to 12 weeks. The 
average time taken for initial repigmentation along with S.D is 6.93±2.8 
weeks. (Table:5) 
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3) Mean grade of treatment response 
Area wise mean grade of repigmentation after five months therapy is 
as follows, Face - 1.83, Neck - 1.8, Anterior trunk - 1.33, Posterior trunk - 
1.5, Upper limb - 1.67, lower limb - 1.57, Hands - 1.07, feet - 1  and at the 
end of treatment as follows Face - 2.16, Neck - 2.6, Anterior trunk - 2.16, 
Posterior trunk - 2, Upper limb - 2.5, lower limb - 2.38, Hands - 1.28, feet - 
1.18. (Table 6, 8)  
At the end of 5 months of therapy 2 persons (13%) are in grade 1, 12 
persons (80%) are in grade 2, 1 person (7%) is in grade 3. At the end of the 
treatment 1 person (7%) is in grade 1, 7 persons (46.5%) are in grade 2, 7 
persons (46.5%) are in grade 3. (Table : 10) 
 The mean grade of treatment response at 5 months is 1.45 whereas. 
Mean grade of treatment response at the end of the treatment is 2.01            
(Table : 13)  
After excluding the resistant sites i.e hands and feet, the mean grade of 
treatment response at 5 months is 1.61 and at the end of the treatment is 2.3 
(Table : 14).  
COLOUR MATCH:   
 Only in 7 patients the colour of repigmentation is same as that of 
surrounding skin, whereas in 8 patients the repigmentation was darker than 
the surrounding skin. (Table: 15)  
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PSYCOLOGICAL SATISFACTION:  
 Out of the 15 patients 8 patients (53%) has good satisfaction, 6 
patients has only moderate satisfaction. One patient was not satisfied with 
the treatment.  
SIDE EFFECTS:  
 6 patients (40%) experienced side effects. Nausea and vomiting 
occured in 2 patients, itching and burning sensation were noted in 4 patients.  
NB-UVB GROUP:  
1) Demographic profile 
In NB-UVB group age of the patient ranges from 18-65 yrs. Mean age 
with S.D(S.D) is 34.±12.80. There are 5 males and 10 females. (Table: 1,2) 
 The duration of disease ranges from 2 yrs to 10 yrs. Mean duration of 
Vitiligo with S.D is 4.96±3.67. (Table:3) The body surface area affected by 
vitiligo ranges from 13% to 48%. Mean body surface area affected by 
vitiligo with S.D is 23.83±11 (Table:4). The duration of therapy ranges from 
6 months to 10 months. The mean duration of therapy with S.D is 7.26±1.22. 
(Table 1 & 2) 
 
 
 
48 
 
2) Initial Repigmentation:  
 Time taken for initial repigmentation ranges from 4 to 12 weeks. The 
average time taken for initial repigmentation in NB-UBV groups is 6.6 ±2.6 
weeks (Table:5)   
3) Mean grade treatment response 
Area wise mean grade of repigmentation after five months of therapy 
is as follows Face - 2, Neck - 1.67, Anterior trunk - 2.36, Posterior trunk - 
2.2, Upper limb - 2, lower limb - 1.84, Hands - 1.2, feet - 1.07, at the end of 
treatment as follows Face - 3, Neck  - 2.67, Anterior trunk - 3.18, Posterior 
trunk - 3, Upper limb - 2.9, lower limb - 2.69, Hands - 1.53, feet - 1.4. 
(Tables: 7,9) 
At the end of 5 months of therapy 4 persons (27%) are in grade 1, 9 
persons (60%) are in grade 2, 3 persons (13%) are in grade 3. At the end of 
the treatment 1 person (7%) is in grade 1, 3 persons (20%) are in grade 2, 7 
persons (46.5%) are in grade 3, 4 persons are in grade 4. (Table:10) 
 The mean grade of treatment response at 5 months is 1.71. Mean 
grade of treatment response at the end of the treatment is 2.5. (Table:13) 
After excluding the resistant sites i.e hand and foot grade of treatment 
as follows. The mean grade of treatment response at 5 months is 2.01 Mean 
grade of treatment response at the end of the treatment is 2.9. (Table:14) 
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COLOUR MATCH:   
 Repigmentation occurred in Vitiligo patches after treatment was 
exactly same as that of surrounding skin in 13 patients. Only in 2 patients 
repigmentation is darker than surrounding skin that too only in the margins. 
(Table:15) 
 PSYCOLOGICAL SATISFACTION:  
 Out of the 15 patients one patient has excellent satisfaction, 9 patients 
has good satisfaction. 3 patients reveal only moderate satisfaction. One 
patient was not satisfied with the treatment  
SIDE EFFECTS:  
 Out of 15 patient 5 patients developed side effects. Itching is the 
common side effect which was noticed in 4 patients. One patient developed 
blisters in lip on first day of therapy which cleared within 2 days.  
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Table : 1. Demographics and patient parameters 
 PUVA NB-UVB 
Number of patients 15 15 
Age in years (Mean ±SD) 41.06±13.63 34±12.80 
Range in years 18-65 18-60 
Sex (Male/Female) 4/11 5/10 
Duration of the Disease in years  
(Mean ±SD) 
4.53±2.19 4.96±3.67 
Range in years 2-10 2-15 
Body surface area in percentage 
(Mean ±SD) 
24.9±9.95 23.83±11.96 
Range in percentage 13-48 11-47 
Duration of therapy in Months 
(Mean±SD) 
6.85±0.99 7.26±1.22 
Range (Months) 6-8 6-10 
 
 
 
Table: 2. Age and sex wise distribution 
 
 
Age Group 
(Years) 
PUVA NB-UVB 
Male (%) Female (%) Male  (%) Female (%) 
18-30 1(6.6%) 3(20%) 2(13%) 4(26.6%) 
31-40 1 (6.6%) 1 (6.6%) 0 (0%) 3 (20%) 
41-50 1(6.6%) 2 (13%) 2(13%) 3 (20%) 
51-60 2(13%) 4(26.6%) 0(0%) 1 (6.6%) 
TOTAL 5(33%) 10 (67%) 4(26.6%) 11(73.4%) 
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Table :3. Comparison of duration of disease in years between two 
groups 
Duration 
(years) 
PUVA NBUVB Mean±S.D 
‘t’ 
Test SignificanceNo of 
patients % 
No of 
patients % PUVA NBUVB 
1-5 9 60.0 8 53.4 
4.53 
± 
2.19 
4.96 
± 
3.67 
0.392 P>0.05 
6-10 5 33.3 5 33.3 
11-15 1 6.7 2 13.3 
Total 15 100.0 15 100.0
 
Table :4. Comparison of body surface area affected by vitiligo between 
both groups 
Surface area 
(percentage) 
PUVA NBUVB Mean±S.D 
‘t’ 
test 
significan
ce 
No of 
patien
ts 
% 
No of 
patien
ts 
% PUVA NBUVB 
10-20 4 26.7 7 46.7 
24.8 
± 
10.0 
23.8 
± 
12.0 
0.24
1 
P>0.05 
20-30 8 53.3 2 13.3 
30-40 2 13.3 4 26.7 
40-50 1 6.7 2 13.3 
TOTAL 15 100.0 15 100.0 
 
Table :5. Comparison of time taken for initial repigmentation between 
both groups 
Duration 
(weeks) 
PUVA NB-UVB Mean ± S.D Chi-
squa
re 
value 
d.f 
Signi
fican
ce 
No 
of 
patie
nts 
% 
No of 
patie
nts 
% PUVA NBUVB 
4 - 7 8 53.4 11 73.4 
6.9 
±2.6 
6.6 
±2.6 
5.400 1 
P>0.0
5 
8 – 11 5 33.3 2 13.3 
12 - 15 2 13.3 2 13.3 
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Table: 6. Treatment Response for PUVA Therapy at 5 Months 
(Response in Grades*) 
 
S 
No Name Face Neck
Ant 
Trunk
Post 
trunk UL LL Hands Feet
Average 
grade of 
response
1 Ramaiah - 2 1 - 2 2 1 1 1.5 
2 
Mohamed 
Hasan 
2 - - - 2 2 1 1 1.6 
3 Elizabeth - - 1 - 2 2 - - 1.67 
4 Pakiathai 2 - - - - 2 1 1 1.5 
5 Hussain 2 - 2 - - 2 1 1 1.6 
6 Parvathi 1 - 1 1 1 1 1 1 1 
7 Lakshmi 1 - - - 1 1 1 1 1 
8 Panchatcharam 2 2 - - 2 1 1 1 1.5 
9 Sundar Rajan 2 - - - 2 1 1 1 1.4 
10 
Muthu 
Lekshmi 
2 - - - 1 1 1 - 1.25 
11 Princy 2 - 2 2 3 3 2 1 2.14 
12 Regina Banu 2 1 1 - - 1 1 1 1.17 
13 Sundari 2 - - - 2 2 1  1.75 
14 Subathra Devi 2 2 - - 1 - 1 - 1.5 
15 Prema - 2 - - 1 1 1 1 1.2 
 
Average 
Pigmentation 
1.83 1.8 1.33 1.5 1.67 1.57 1.07 1 1.45 
 
Grade  : 0 = 0 % (No Response) 
Grade  :  1 = 1-25% (Mild) 
Grade  :  2 = 26-50% (Moderate) 
Grade  :  3 = 51-75% (Good) 
Grade  :  4 = 76-99% (Very Good) 
Grade :  5 = 100% (Excellent) 
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Table:7. Treatment Response for NB-UVB Therapy at 5 Months 
(Repigmentation in Grades*) 
S 
No 
Name Face Neck 
Ant 
Trunk
Post 
Trunk
UL LL Hands Feet
Average 
grade of 
response
1 Arunachalam 2 - 3 2 3 2 1 1 2 
2 Arumugam 2 - 2 - - - 1 1 1.5 
3 Angela 2 - - - - 3 1 1 1.75 
4 Subbulaksmi 1 - - - - 1 1 1 1 
5 Gayathridevi 2 - 2 2 2 2 2 1 1.85 
6 Kaliraj 1 1 1 1 1 1 1 1 1 
7 Sarathu - - 3 3 3 - 2 2 3.2 
8 Ramalingam 2 2 2 2 2 2 1 1 1.75 
9 Gomathi 1 1 - - - 1 1 1 1 
10 Gururajan 3 2 3 3 2 2 2 1 2.25 
11 Sujatha 2 2 1 2 2 2 1 1 1.62 
12 Manjula - - - - 1 1 1 1 1 
13 Rajashree - - 3 3 2 3 1 1 2.17 
14 Daisy 3 2 2 2 2 2 1 1 1.87 
15 
Mary 
Merceline 
3 - 2 2 - 2 1 1 1.83 
 
Average 
Pigmentation 
2 1.67 2.36 2.2 2 1.84 1.2 1.07 1.71 
 
Grade : 0  = 0 %  (No Response) 
Grade : 1  = 1-25%  ( Mild) 
Grade : 2  = 26-50%  (Moderate) 
Grade : 3  = 51-75%  (Good) 
Grade : 4  = 76-99% (Very Good) 
Grade : 5  = 100%  (Excellent) 
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Table:8. Treatment Response for PUVA Therapy at the end of the 
treatment 
(Response in Grades*) 
S 
No 
Name Face Neck
Ant 
Trunk
Post 
trunk
UL LL Hands Feet
 
1 Ramaiah - 3 2 - 3 3 1 1 2.16
2 
Mohamed 
Hasan 
2 - - - 3 3 1 1 2 
3 Elizabeth - - 2 - 3 2 - - 2.3 
4 Pakiathai 3 - - - - 3 1 1 2 
5 Hussain 2 - 3 - - 3 2 2 2.4 
6 Parvathi 1 - 1 1 1 1 1 1 1 
7 Lekshmi 1 - - - 2 2 1 1 1.4 
8 Panchatcharam 2 3 - - 3 2 1 1 2 
9 Sundar Rajan 3 - - - 3 2 1 1 2 
10 Muthu Lekshmi 2 - - - 2 2 2 - 2 
11 Princy 3 - 3 3 4 4 2 1 2.85
12 Regina Banu 2 2 2 - - 2 1 2 1.83
13 Sundari 3 - - - 3 3 2 2 2.6 
14 Subathra Devi 2 3 - - 2 - 2 - 2.25
15 Prema - 2 - - 2 1 1 1 1.4 
 
Average 
Pigmentation 
2.16 2.6 2.16 2 2.5 2.38 1.28 1.18 2.01
 
Grade : 0  = 0 %  (No Response) 
Grade : 1  = 1-25%  (Mild) 
Grade : 2  = 26-50%  (Moderate) 
Grade : 3  = 51-75%  (Good) 
Grade : 4  = 76-99% (Very Good) 
Grade : 5  = 100%  (Excellent) 
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Table:9. Treatment Response for NB-UVB Therapy at the end of 
treatment 
(Response in Grades*) 
S 
No 
Name Face Neck
Ant 
Trunk
Post 
Trunk
UL LL Hands Feet  
1 Arunachalam 5 - 5 3 4 3 1 1 3.1 
2 Arumugam 2 - 3 - - - 2 2 2.25 
3 Angela 4 - - - - 3 2 2 2.75 
4 Subbulaksmi 2 - - - - 2 1 1 1.5 
5 Gayathridevi 2 - 3 2 3 3 2 1 2.28 
6 Kaliraj 1 1 1 1 1 1 1 1 1 
7 Sarathi - - 4 4 4 - 3 3 3.6 
8 Ramalingam 3 3 2 3 3 3 1 1 2.63 
9 Gomathi 2 2 - - - 2 1 1 1.6 
10 Gururajan 4 4 4 4 3 3 2 1 3.25 
11 Sujatha 3 3 3 3 3 3 1 1 2.5 
12 Manjula - - - - 2 2 1 1 1.5 
13 Rajashree - - 4 4 3 4 2 2 3.2 
14 Daisy 4 3 3 3 3 3 1 1 2.63 
15 
Mary 
Merceline 
4 - 3 3 - 3 2 2 3 
 
Average 
Pigmentation 
3 2.67 3.18 3 2.9 2.69 1.53 1.4 2.45 
 
Grade : 0  = 0 %  (No Response) 
Grade : 1  = 1-25%  ( Mild) 
Grade : 2  = 26-50%  (Moderate) 
Grade : 3  = 51-75%  (Good) 
Grade : 4  = 76-99% (Very Good) 
Grade : 5  = 100%  (Excellent) 
56 
 
Table :10.  Grading of repigmentation obtained including Resistant sites 
 
Grade 
5 Months 
At the End of the 
Treatment 
PUVA NB-UVB PUVA NB-UVB 
Number of patients (%) Number of patients (%) 
0 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
1 2 (13%) 4 (27%) 1 (7%) 1 (7%) 
2 12 (80%) 9 (60%) 7 (46.5%) 3 (20%) 
3 1 (7%) 2 (13%) 7 (46.5%) 7 (46.5%) 
4 0 (0%) 0 (0%) 0 (0%) 4 (26.5 %) 
5 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 
 
Table : 11. Grading of repigmentation obtained excluding Resistant sites 
 
Grade 
5 Months 
At the End of the 
Treatment 
PUVA NB-UVB PUVA NB-UVB 
Number of patients (%) Number of patients (%) 
0 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
1 2 (13%) 4 (26.5%) 1(7%) 1 (7%) 
2 12 (80%) 4 (26.5%) 4 (26%) 3 (20%) 
3 1 (7%) 7 (47%) 9 (60%) 6 (40%) 
4 0 (0%) 0 (0%) 1 (7%) 5 (33%) 
5 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
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Table : 12. Topographical areawise repigmentation at the end of 
treatment  
 
Topographic
al area 
Mode of 
therapy 
No of Patients 
Total Number of 
Patients 
With 
involvement 
N
o 
R
es
po
ns
e 
0 
%
 
0-
25
%
 
26
-5
0%
 
51
-7
5%
 
76
-9
9%
 
10
0%
 
Face 
PUVA 0 2 6 4 0 0 12 
NB-UVB 0 1 4 2 4 1 12 
Neck 
PUVA 0 0 2 3 0 0 5 
NB-UVB 0 1 1 3 1 0 6 
Anterior 
trunk 
PUVA 0 1 3 2 0 0 6 
NB-UVB 0 1 1 5 3 1 11 
Posterior 
trunk 
PUVA 0 1 0 1 0 0 2 
NB-UVB 0 1 1 5 3 0 10 
Upper limbs 
PUVA 0 1 4 6 1 0 12 
NB-UVB 0 1 1 6 2 0 10 
Lower limbs 
PUVA 0 2 6 5 1 0 13 
NB-UVB 0 1 3 8 1 0 13 
Hands 
PUVA 1 8 5 0 0 0 14 
NB-UVB 0 8 6 1 0 0 15 
Feet 
PUVA 1 8 3 0 0 0 12 
NB-UVB 0 10 4 1 0 0 15 
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Table :13. Comparison of mean grade of treatment response between 
PUVA and NB-UVB therapy including the resistant site 
Period 
PUVA NB-UVB Differenc
e of mean 
‘t’ 
Test 
d.f 
signific
ance Mean S.D Mean S.D 
At 5th 
month 
1.45 0.3 1.7 0.6 0.3 1.556 28 p>0.05 
At the end 
of the 
treatment 
2.01 0.4 2.5 0.8 0.4 2.086 28 P<0.05 
 
 
Table : 14. Comparison of mean grade of treatment response of two 
group excluding resistant site (without hands and feet) 
 
Period 
PUVA NB-UVB Differe
nce of 
mean 
‘t’ 
Test 
d.f 
signific
ance Mean S.D Mean S.D 
At 5th 
month 
1.61 0.2 2.01 0.2 0.4  28 P>0.05 
At the end 
of the 
treatment 
2.3 0.6 2.9 0.9 0.6 2.185 28 P<0.05 
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Table :15. Comparison of Colour match between both groups 
 
Colour 
match 
PUVA NB-UVB 
Chisqur
e value 
d.f 
Sign
ifica
nce 
Mean S.D Mean S.D 
Darker 8 53.3 2 13.3 
5.400 1 
P<0.
05 
Same 7 47.7 13 86.7 
Total 15 100 15 100 
 
 
 
TABLE :16. Impact of duration of treatment on Repigmentation 
 
Group At 5TH 
Month 
At the end Improvement ‘t’ d.f Significance
MEAN S.D MEAN S.D MEAN S.D 
PUVA 1.4 0.3 2.0 0.4 0.6 0.2 6.389 14 P<0.001 
NBUVB 1.7 0.6 2.5 0.8 0.8 0.3 8.615 14 P<0.001 
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DISCUSSION 
 Psoralen with Ultra violet A therapy (PUVA) is a well established 
treatment for Vitiligo vulgaris. It is used in the present form since 1976. 
However puvasol therapy has been in use since 2500 years (yrs).[11] 
 In 1997, Narrow Band Ultra Violet B therapy (NBUVB) was 
introduced by westerhof et al for vitiligo vulgaris management. NBUVB has 
been found to be effective in vitiligo in various studies over the period.[61] 
There are only few studies comparing the efficacy and safety of 
PUVA and NBUVB therapy in the treatment of Vitiligo[57&58&59&60], this is 
one such study. 
Demographic and disease parameters: 
 In this study, in the PUVA group age of the patients ranges from            
18-65 years whereas in NB-UVB group age of the patient ranges from 18-65 
years. The mean age of patient with standard deviation (S.D) in PUVA group 
is 41.06±13.63 whereas in NBUVB is 34±12.80, this variation in age group 
is not statistically significant.  Similar age parameters are found in study by 
Bhatnagar et al.,59  and study by Sami Sasi Yones, et al.58. (Table: 1&2) 
 In this study, there are 4 males and 11 females in PUVA group and 5 
males and 10 females in NBUVB group. Similar male to female ratio found 
in study by Bhatnagar et al.59, (Table:2). This higher number of female 
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patients in each group is probably due to increased cosmetic concern 
expressed by female patients.  
 In this study all the 30 patients were of Vitiligo vulgaris type.Most of 
the patients had Vitiligo patches over face,upper and lower limbs. Only some 
patients had trunk involvement. In the study  by  Bhatnagar et al.59, in PUVA 
group 23 patients had Vitiligo vulgaris whereas one patient each had focal 
and acrofacial involvement and in NBUVB group all 25 patients had Vitiligo 
vulgaris. 
In this study, the duration of disease in PUVA group ranges from 2 yrs 
to 15 yrs whereas in NBUVB group 2 yrs to 10 yrs. Mean duration of disease 
in PUVA group is 4.53±2.19 whereas in NBUVB group is 4.96±3.67.(Table: 
1,3). The difference between the mean duration of Vitiligo in both groups 
was statistically not significant (p>0.05). Study by  Bhatnagar et al.59, mean 
duration of treatment in PUVA group is 4.36±2.94 whereas in NBUVB is 
11.24±7.6 which is not concurrent to this study. 
The body surface area affected by vitiligo in PUVA group ranges from 
13% to 48% whereas in NBUVB 11% to 47%. Mean body surface area 
affected by vitiligo in PUVA group is 24.9±9.95 whereas in NBUVB is 
23.83±11.96 (Table:4). The difference of mean surface area affected by 
Vitiligo between two groups was statistically not significant. Similar body 
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surface area involvement is seen in Study by  Bhatnagar et al.5a.  and parsad 
et al. 
The duration of treatment taken by PUVA group ranges from 6 
months to 8 months whereas in NBUVB it is 6 months to 10 months. The 
mean duration of therapy in PUVA group is 6.85±0.99 whereas treatment  in 
NBUVB group 7.26±1.22. Which is comparable to  the duration of treatment  
seen in study by Sami Sasi Yones, et al.58. But, in the study by  Bhatnagar et 
al.59,  , it is slightly  less (6.3±1.71 in NBUVB, 5.64±1.8 in PUVA) 
In this study, comparing the demographic and disease parameters 
between  the two groups, no statistically significant differences were found. 
Which is comparable to the study done by Sami Sasi Yones, et al5.   In the 
study by Bhatnagar et al.59 also no statistically significant differences were 
found in any of the variables except for total disease duration, which was 
more in the NBUVB group(Table:1).  
Treatment response: 
In this study, time taken for initial repigmentation ranges from 4 
weeks to 12 weeks in both groups. The average time taken for initial 
repigmentation in NB-UBV groups is 6.6±2.6 weeks whereas in PUVA 
group is 6.93±2.8 weeks. This is similar to the study by Bhatnagar et al,59. 
This difference was not statistically significant(Table:5).  
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None of the patient in both groups showed 100%(grade 5) response 
and also 0%(Grade 0) response. Overall, 11 persons(73.3%) are in grade 3 
and 4 treatment response in NB-UVB group where as only 7 persons(46.6%) 
in PUVA group. Four persons (26.5%) in NB-UVB group showed grade 4 
response where as in PUVA group there were no person in the grade 4 
response seen at the end of the treatment. (Table 10). However after 
excluding the resistant sites that is hands and feet, 1 person in the PUVA 
group and 5 persons in the NB-UVB group showed grade 4 response. 
Overall 11 persons(73%) are in grade 3 and 4 response in NB-UVB group 
whereas only 10 persons(67%) in PUVA group after excluding resistant sites 
(Table:11). This shows in NB-UVB group the treatment response is better 
than PUVA group. Similar report were found in study by Parsad et al. 
In this study, (Table: 6, 7&13) comparing the treatment response at 
five months there is no statistically significant difference (PUVA 1.45 
NBUVB 1.71). Mean grade of treatment response at the end of the treatment 
in PUVA therapy is 2.01 whereas in NBUVB 2.5. (Table8,9&13) Comparing 
the treatment response at end of treatment there is statistically significant 
difference between both groups. Study by Parsad et al., showed similar 
result. This is in contrary to study by Bhatnagar et al.  Even after excluding 
the resistant sites i.e hands and feet ‘,the mean grade of treatment response at 
5 months there is no statically significant difference. Mean grade of 
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treatment response at the end of the treatment after excluding resistant sites 
in PUVA therapy is 2.34 whereas in NB-UVB it is 2.9. This difference is 
statistically significant(Table: 14) study by Bhatnagar et al and Parsad et al 
showed similar results. 
Minimal mean grade of treatment response (Grade 1) was seen in 
hands and feet in both groups (Table :12). Comparable results were found in 
the study by Bhatnagar et al59, Sami, sasi yonus et al also. Area wise 
assessment of repigmentation showed greater pigmentation  seen in face and 
trunk lesions in the NBUVB group. In the PUVA group greater pigmentation 
seen in neck and limb lesions. In this study the lower grade of facial 
repigmentation seen in PUVA may probably due to the fact that in the face 
only lips are commonly affected by Vitiligo in this group.  
Colour match in Vitiligo patches after NBUVB treatment was exactly 
same as that surrounding skin in 13 patients (86%). Only in 2 patients (14%) 
repigmentation is darker than surrounding skin that too only in the margins. 
In study by Sami Sasi Yones et al.58, all patients had exactly the same colour 
compare to the surrounding skin in NBUVB group. Study by Bhatnagar et 
al.59, 22 persons (88%) showed same colour match. This colour match was 
cosmetically very appealing to the patient which improves the psychological 
satisfaction felt by the patient. (Table : 15) 
65 
 
 In PUVA group, only in 7 patients (46%) the colour match is same as 
that of surrounding skin, whereas in 8 patients (54%) the colour match was 
darker than the surrounding skin. Study by Bhatnagar et al.,59  in PUVA 
group 11 (44%) patients out of 25 had somewhat darker colour. In the study 
by Sami sasi Yones et al58., in PUVA group 14 (61%) patients out of 25 had  
ecact colour match. Considering the colour match, there is statistically 
significant difference between both groups p<0.05. (Table:15) 
Excellent satisfaction was seen in 1 patient in NBUVB group, but no 
patients in PUVA group. Nine patients in NBUVB group and 6 patients in 
PUVA group experienced good satisfaction. Considering the psychological 
satisfaction, there is no statistically significant difference between both 
groups p<0.05. 
Side effects are minimal in both groups. None of the patient stopped 
the treatment because of side effects in both groups. Itching is the common 
side effect noticed in NBUVB group which occurred in 4 patients (26%). 
One patient developed blisters in lip on first day of therapy which cleared 
within 2 days. Side effect like Nausea and vomiting were not noticed NB 
UVB group. Study by  Bhatnagar et al.59  9 patients(36%) experienced side 
effects ( herpes labialis in 4 patients, mild to moderate itching in 3 patients, 
urticaria in 1 patients and symptomatic dermographism in 1 patient) but 
Herpes labialis is not noticed in this study.  
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In PUVA therapy side effect were noticed in 6 patients (40%). Nausea 
and vomiting occurred in 2 patients, itching and burning sensation were 
noted in 4 patients. However, the Nausea and vomiting is not severe enough 
to stop the therapy. They were managed by giving Psoralen along with food 
and symptomatic treatment. Study by  Bhatnagar et al.59,1  13 patients(52%) 
experienced side effects. (Itching in 4 patients, sedation in 3 patients, xerosis 
in 3 patients, Exacerbation of  acne lesions in 3 patients, nausea in 2 
patients). Considering the side effect, there is no statistically significant 
difference between both groups (p<0.05). 
 There is a consistent improvement in treatment response as the 
duration of therapy increases. (Table:16).  Study by Harikrishnan kumar et 
al11 it is stated that good response is directly associated with more number of 
exposure, cumulative dose and good compliance. Our study also established 
this fact.  
Comparing NBUVB therapy with PUVA therapy, like many other 
studies, our study also establish the fact that both PUVA therapy and 
NBUVB therapy are efficacious in treatment of  Vitiligo. NBUVB therapy is 
superior to PUVA therapy in term of mean degree of repigmention colour 
match and psychological satisfaction experienced by the patient. 
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SUMMARY 
 This open prospective comparative study was conducted to compare 
the safety and efficacy of PUVA therapy and NBUVB therapy in the 
treatment of Vitiligo. 
 The demographic and disease parameters were comparable between 
each group. 
 The difference in the time taken for initial repigmentation between 
both groups is not statistically significant.  
 There is consistent improvement in the treatment response in each 
group from onset as the duration of treatment increases.  
 At the end of 5 months, the mean grade of treatment response is 
slightly better in NBUVB group compared to PUVA group, however it is 
statistically not significant.  
 At the end of treatment, the mean grade of treatment response in 
NBUVB group is higher than that in the PUVA group. This difference is 
statistically significant.  
 The colour match same as that of surrounding skin is seen in 86% of 
patient in NBUVB group whereas only 46% in PUVA group. This same 
colour match is cosmetically very appealing to the patients and it increases 
the psychological satisfaction.  
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The mean grade of treatment response increases in both groups after 
excluding the resistant sites (i.e., hands and feet).  
 Minimal response is seen in hands and feet in both groups. Face and 
trunk lesions showed maximal response in NBUVB. PUVA group neck 
lesion showed maximal response.  
Patient in NBUVB group had greater psychological satisfaction 
compare to PUVA group. However, the difference is not statistically 
significant. 
 Patient in NBUVB group had lesser side effects than PUVA group. 
However, it is not statistically significant.  
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CONCLUSION 
 
The NBUVB groups showed better response in all the treatment 
response parameter compared. There was a statistically significant 
improvement seen in mean grade of treatment response at the end of 
treatment and the colour match. In the treatment of vitiligo NBUVB therapy 
is superior to PUVA therapy. However studies with larger group of patient 
and longer duration of treatment and follow up are essential to reveal further 
differences or to confirm the result of this study.   
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ABBREVIATION 
 
8MOP   - 8 Methoxy Psoralens 
D.f   - Degree of freedom 
H2O2   - Hydrogen peroxide 
HLA   - Human Leucocyte Antigen 
ICAM   - Inter Cellular Adhesion Molecule 
NBUVB   - Narrow Band ultraviolet B 
NSV   - Non segmental Vitiligo 
PG   - Prostaglandin 
PUVA   - Psoralen Ultraviolet A 
S.D   - Standard Deviation 
TMP   - 4, 5, 8 – Trimethyl psorlens 
TNF α   - Tumor necrosis factor α 
VASI   - Vitiligo Area severity Index 
 
 
 
 
 
 
 
Comparative Study of PUVA Therapy & NBUVB in Vitiligo Vulgaris 
 
PROFORMA 
 
Name :    Skin OP No. :  Date : 
Age :    Sex :    Occupation : 
Address :        Phone : 
 
Presenting complaint (S) : 
 
Onset 
Duration 
Progression 
Area of Involvement 
Initial Photograph 
 
 
 
 
 
 
 
Treatment History 
 
History of Photosensitivity 
 
History of Past Illness 
 
Associated diseases 
 
DM/HT/Thyroid disease / anemia / Other Auto immune disease 
Personal History 
 
Family History 
Investigation 
HB% 
TC 
DC 
Blood Sugar (R) 
Blood Urea 
Creatinine 
Thyroid function tests 
Liver functions tests 
Auto antibodies 
Treatment Schedule 
S.No. Date Dose Cumulative dose Follow up & Remarks 
1.     
2.     
3.     
4.     
5.     
6.     
7.     
8.     
9.     
10.     
11.     
12.     
13.     
14.     
15.     
16.     
17.     
18.     
19.     
20.     
21.     
22.     
23.     
24.     
25.     
26.     
27.     
28.     
29.     
30.     
 
WEEKLY TREATMENT RESPONSE 
 
S.No. Wks Face Neck AT PT UL LL Hand Sat Mean
 2          
 4          
 6          
 8          
 10          
 12          
 14          
 16          
 18          
 20          
 22          
 24          
 26          
 28          
 30          
 32          
 34          
 36          
 
 
 
 
Initial surface areas affected by Vitiliogo 
 
Treatment response at the end 
 
  
 
 
 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
PUVA Therapy – Initial Photograph 
 
 
PUVA Therapy – End of treatment  - Grade 3 Response 
 
PUVA Therapy – Initial photograph 
 
 
PUVA Therapy – End of treatment – Grade 1 Response 
 
 
PUVA Therapy – Initial photograph (Lower back lesion) 
 
 
PUVA Therapy – End of treatment – Grade 4 Response 
 
PUVA Therapy – Initial Photograph 
 
 
PUVA Therapy – End of treatment – Grade 3 Response 
 
PUVA Therapy – Intial Photograph 
 
 
PUVA Therapy – End of treatment – Grade 3 Response 
 
NBUVB Therapy – 5 months – Anterior Trunk 
 
NBUVB Therapy – End of treatment – Grade 2 Response 
 
NBUVB Therapy – Initial Photograph 
 
NBUVB Therapy End of treatment – Grade 3 Response 
 
NBUVB Therapy Initial Photograph 
 
 
NBUVB Therapy End of treatment – Grade 1 Response 
 
NBUVB Therapy – Initial Photograph 
 
NBUVB Therapy – End of treatment – Grade 4 Response 
 
NBUVB Therapy – Initial photograph (Lower Back lesion) 
 
 
NBUVB Therapy – End of treatment – Grade 4 Response 
 
NBUVB Therapy – Initial photograph 
 
NBUVB Therapy – End of treatment – Grade 4 Response 
 
Phototherapy Unit 
(UVA & NBUVB) 
 
 
 
 NB‐UVB MASTER CHART 
    * 
Grade : 0  = 0 %  (No Response) Grade : 1  = 1‐25%  ( Mild) Grade : 2  = 26‐50%  (Moderate)  Grade : 3  = 51‐75%  (Good)   Grade : 4 = 76‐99% (Very Good)   Grade: 5  = 100%  (Excellent)  
 
‐   =  Areas not affected  
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Area wise Repigmentation at 5 
months (Grade*)  
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Area wise Repigmentation at end of 
the Treatment (Grades*)  
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1 Arunachalam 40 F House Wife 5 2 30 4  Nil Nil Normal 2 - 3 2 3 2 1 1 2 5 - 5 3 4 3 1 1 3.1 10 
Darker 
 Excellent 
Blisters in 
lip 
2 Arumugam 43 F Labourer 15 10 10.5 6  Nil Nil Normal 2 - 2 - - - 1 1 1.5 2 - 3 - - - 2 2 2.25 6 Same Good - 
3 Angela 48 F Teacher 3 2 11 4  Nil Nil Normal 2 - - - - 3 1 1 1.75 4 - - - - 3 2 2 2.75 6 Same Moderate - 
4 Subbu Lakshmi 20 F Student 5 2 11 12  Nil Nil Normal 1 - - - - 1 1 1 1 2 - - - - 2 1 1 1.5 7 Same Moderate - 
5 Gayathri Devi 18 F Student 3 1 47 6 Nil Nil Normal 2 - 2 2 2 2 2 1 1.85 2 - 3 2 3 3 2 1 2.28 7 Same Good Itching 
6 Kaliraj 25 M Salesman 10 7 22 12  Nil Nil Normal 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 Same Unsatisfied - 
7 Sarathi 45 M Merchant 3 1 20 6  Nil Nil Normal - - 3 3 3 - 2 2 3.2 - - 4 4 4 - 3 3 3.6 7 Darker Good - 
8 Ramalingam 45 M Merchant 7 2 32 4  Nil Nil Normal 2 2 2 2 2 2 1 1 1.75 3 3 2 3 3 3 1 1 2.38 8 Same Excellent - 
9 Gomathi 60 F House Wife 6 3 12 8  Nil Diabetic 
Norm
al 1 1 - - - 1 1 1 1 2 2 - - - 2 1 1 1.6 6 Darker Good Itching 
10 Gururajan 30 M Attender 2 1 31 4  Nil Nil Normal 3 2 3 3 2 2 2 1 2.25 4 4 4 4 3 3 2 1 3.25 8 Same Good - 
11 Sujatha 18 F Student 1.5 1 43 6  Nil Nil Normal 2 2 1 2 2 2 1 1 1.62 3 3 3 3 3 3 1 1 2.5 7 Same Moderate Itching 
12 Manjula 34 F House Wife 2 1 16 6  Nil Nil Normal - - - - 1 1 1 1 1 - - - - 2 2 1 1 1.5 6 Same Good - 
13 Rajashree 32 F House Wife 3 1 18 6  Nil Nil Normal - - 3 3 2 3 1 1 2.17 - - 4 4 3 4 2 2 3.2 8 Same Good - 
14 Daisy 34 F Teacher 7 3 36 7  Nil Nil Normal 3 2 2 2 2 2 1 1 1.87 4 3 3 3 3 3 1 1 2.63 9 Same Good - 
15 Mary Merceline 18 F Student 2 1 18 8  Nil Nil Normal 3 - 2 2 - 2 1 1 1.83 4 - 3 3 - 3 2 2 3 8 Same Good - 
PUVA MASTER CHART 
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Area wise Repigmentation at 5 months 
(Grades*) 
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Area wise Repigmentation at end of 
the Treatment (Grades*) 
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1 Ramaiah 60 M labourer 3 2 20 4 Nil Nil Normal - - 2 1 - 2 2 1 1.5 - 3 2 - 3 3 1 1 2.16 7 Same Good - 
2 Mohamed Hassan 56 M Labourer 7 4 26 8 Nil Diabetic Normal 2 2 - - - 2 2 1 1.6 2 - - - 3 3 1 1 2 8 Same Good Vomiting 
3 Elizabeth 46 F House wife 3 2 27 10 Nil Nil Normal - - - 1 - 2 2 - 1.67 - - 2 - 3 2 - - 2.3 7 Same Good - 
4 Pakiathai 46 F Labourer 10 3 20 4 Nil Nil Normal 2 2 - - - - 2 1 1.5 3 - - - - 3 1 1 2 8 Same Good Itching Burning 
5 Hussain 30 M Attender 3 1 21 12 Nil Nil Normal 2 2 - 2 - - 2 1 1.6 2 - 3 - - 3 2 2 2.4 8 Darker Good - 
6 Parvathi 55 F House wife 6 5 38 12 Nil Nil Normal 1 1 - 1 1 1 1 1 1 1 - 1 1 1 1 1 1 1 6 Same Unsatisfied Nausea 
7 Lakshmi 56 F Labourer 4 2 13 4 Nil Nil Normal 1 1 - - - 1 1 1 1 1 - - - 2 2 1 1 1.4 6 Same Moderate Itching 
8 Panchatcharam 45 M Labourer 5 2 21 6 Nil Nil Normal 2 2 2 - - 2 1 1 1.5 2 3 - - 3 2 1 1 2 6 Darker Moderate - 
9 Sundhararajan 31 M Teacher 5 2 15 4 Nil Nil Normal 2 2 - - - 2 1 1 1.4 3 - - - 3 2 1 1 2 6 Darker Good - 
10 Muthulakshmi 28 F House wife 2 1 28 6 Nil Nil Normal 2 2 - - - 1 1 1 1.25 2 - - - 2 2 2 - 2 7 Darker Moderate - 
11 Princy 30 F House wife 4 1 48 4 Nil Nil Normal 2 2 - 2 2 3 3 2 2.14 3 - 3 3 4 4 2 1 2.85 8 Darker Good - 
12 Regina banu 18 F Student 2 1 38 6 Nil Nil Normal 2 2 1 1 - - 1 1 1.17 2 2 2 - - 2 1 2 1.83 7 Darker Unsatisfied Itching, burning 
13 Sundari 35 F House wife 4 2 26 8 Nil Nil Normal 2 2 - - - 2 2 1 1.75 3 - - - 3 3 2 2 2.6 8 Darker Good - 
14 Subathra devi 25 F House wife 3 2 16 8 Nil Nil Normal 2 2 2 - - 1 - 1 1.5 2 3 - - 2 - 2 - 2.25 6 Same Moderate Itching 
15 prema 55 F Labourer 7 4 15 8 Nil Nil Normal - - 2 - - 1 1 1 1.2 - 2 - - 2 1 1 1 1.4 6 Darker Moderate - 
    * 
Grade : 0  = 0 %  (No Response) Grade : 1  = 1‐25%  ( Mild) Grade : 2  = 26‐50%  (Moderate)  Grade : 3  = 51‐75%  (Good)   Grade : 4 = 76‐99% (Very Good)   Grade: 5  = 100%  (Excellent)  
 
‐   =  Areas not affected  
 
